RE-BVS – Piemonte Repository

Sfoglia per AUTORE
RUSCONI S
Collezione ASL Città di Torino

Items : 23

Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. in Brain : a journal of neurology / Brain. 2024 Nov 4;147(11):3742-3750. doi: 10.1093/brain/awae271.

2024
ASL Città di Torino

Gulminetti R; Ripamonti D; Antinori A; Muscatello A; Gabrieli A; Bruzzesi E; Rusconi S; Marchetti G; Bernasconi D; Trunfio M; Cinque P; Cusato J; Antonucci M; Calcagno A; Nozza S;

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting. in Viruses / Viruses. 2023 Jul 23;15(7):1612. doi: 10.3390/v15071612.

2023
ASL Città di Torino
AOU Novara
AOU Alessandria

Bonfanti P; Di Biagio A; Ferrara S; Cenderello G; Falasca K; Martini S; Bargiacchi O; Sarchi E; Calza L; Rusconi S; Taramasso L; Valsecchi L; Carleo MA; Cascio A; Parisini A; Pellicanò GF; Vichi F; Celesia BM; Madeddu G; Bellagamba R; Masiello A; Menzaghi B; Orofino G; Ricci ED; Martinelli CV; De Socio GV; Squillace N; Molteni C; Maggi P; et alii...

Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: The DIAMANTE study in Future Virology

2023
ASL Città di Torino

Antinori A; Vergori A; Ripamonti D; Valenti D; Rizzardini G; Cossu MV; Rusconi S; Esposito V; Cascio A; Orofino G; Andreoni M; Manzillo E; Castagna A; Mancusi D; Termini R; Portaro M; Uglietti A;

Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. in AIDS patient care and STDs / AIDS Patient Care STDS. 2021 Sep;35(9):342-353. doi: 10.1089/apc.2021.0089.

2021
ASL Città di Torino
AOU Alessandria

Bonfanti P; Di Biagio A; Madeddu G; Bandera A; Falasca K; Dentone C; Cenderello G; Guadagnino G; Maggi P; Angioni G; Vichi F; Valsecchi L; Martinelli CV; Cascio A; Rusconi S; Celesia BM; Calza L; Pellicanò GF; Sarchi E; Menzaghi B; De Socio GV; Gulminetti R; Molteni C; Ricci ED; Orofino G; Squillace N; Taramasso L; De Vito A;

Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. in HIV medicine / HIV Med. 2020 Sep;21(8):523-535. doi: 10.1111/hiv.12885. Epub 2020 Jun 24.

2020
ASL Città di Torino

Calcagno A; Pinnetti C; Mastrangelo A; Bruzzesi E; De Benedetto I; Nozza S; Fabbiani M; Taramasso L; Ferrara M; Bozzi G; Focà E; Quiros-Roldan E; Ripamonti D; Campus M; Celesia BM; Torti C; Cosco L; Di Biagio A; Rusconi S; Marchetti G; Mussini C; Gulminetti R; Cingolani A; d'Ettorre G; Madeddu G; Franco A; Orofino G; Squillace N; Muscatello A; et alii...

Factors associated with hospital admission for COVID-19 in HIV patients. in AIDS (London, England) / AIDS. 2020 Nov 1;34(13):1983-1985. doi: 10.1097/QAD.0000000000002663.

2020
ASL Città di Torino
AOU Novara

Taramasso L; Bonfanti P; Ferrara S; Saracino A; Falasca K; Maggi P; Valsecchi L; Cenderello G; Molteni C; Bargiacchi O; Orofino G; Rusconi S; Ricci E; Calza L; Squillace N; Menzaghi B; Di Biagio A;

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study. in Journal of acquired immune deficiency syndromes (1999) / J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):290-294. doi: 10.1097/QAI.0000000000002331.

2020
ASL Città di Torino

Sterrantino G; Menzaghi B; Cossu MV; Vergori A; Antinori A; Gori A; Rusconi S; Cattelan AM; Castelli F; Gianotti N; Orofino G; Ripamonti D; Savinelli S; Manzillo E; Santantonio TA; Celesia BM; Cauda R; Maserati R; d'Arminio Monforte A; Stingone C; Bonora S; Uglietti A; Termini R; Rucci F; Mancusi D;

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. in Diabetes care / Diabetes Care. 2020 Dec;43(12):2999-3006. doi: 10.2337/dc20-1521. Epub 2020 Sep 29.

2020
ASL Città di Torino

Galli M; Fiorina P; Folli F; Di Sabatino A; Zuccotti G; Abdi R; Rusconi S; Bonventre JV; De Riva C; Colombo R; Oleandri SE; Mirani M; Corsico A; Catena E; Fiorina RM; Lepore G; Geni F; Dodesini AR; Galliani S; Scaranna C; Bellante R; Pastore I; Dell'Acqua M; Ippolito E; Lovati E; Rossi A; Solerte SB; Trevisan R; D'Addio F; et alii...

Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. in Pathogens & immunity / Pathog Immun. 2020 Feb 24;5(1):8-33. doi: 10.20411/pai.v5i1.341. eCollection 2020.

2020
ASL Città di Torino

Mussini C; Gulminetti R; Cingolani A; D'ettorre G; Madeddu G; Franco A; Orofino G; Squillace N; Muscatello A; Bandera A; Gori A; Tambussi G; Marchetti G; Rusconi S; Cosco L; Di Biagio A; Torti C; Maurizio Celesia B; Pinnetti C; Calcagno A; Ferrara M; Campus M; Ripamonti D; Quiros-Roldan E; Focà E; Antinori A; Dell'acqua R; Ripa M; De Benedetto I; et alii...

Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. in Journal of medical virology / J Med Virol. 2019 Oct;91(10):1891-1895. doi: 10.1002/jmv.25517. Epub 2019 Jun 27.

2019
ASL Città di Torino

Giacomelli A; Fabbiani M; De Benedetto I; Nozza S; Focà E; Celesia BM; Marchetti G; Mussini C; Antinori A; d'Ettorre G; Madeddu G; Bandera A; Muscatello A; Rusconi S;

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. in Journal of acquired immune deficiency syndromes (1999) / J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986.

2019
ASL Città di Torino

Rossetti B; Gagliardini R; Sterrantino G; Colangeli V; Latini A; Colafigli M; Vignale F; Rusconi S; Di Biagio A; Orofino G; Mezzaroma I; Vullo V; Francisci D; Mastroianni C; Trezzi M; Canovari B; Lamonica S; Ciccullo A; Borghetti A; Di Giambenedetto S; De Luca A;

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. in AIDS (London, England) / AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188.

2019
ASL Città di Torino

Castagna A; Rusconi S; Gulminetti R; Bonora S; Mazzola G; Quiros-Roldan ME; De Socio GV; Ladisa N; Carosella S; Cattelan A; Di Giambenedetto S; Mena M; Poli A; Galli L; Riva A;

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. in Journal of the International AIDS Society / J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227.

2019
ASL Città di Torino

Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

2018
ASL Città di Torino

Fabbiani M; Gagliardini R; Ciccarelli N; Quiros Roldan E; Latini A; d'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Del Pin B; Lombardi F; D'Avino A; Focà E; Colafigli M; Cauda R; Di Giambenedetto S; De Luca A;

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. in The Annals of pharmacotherapy / Ann Pharmacother. 2018 Aug;52(8):740-746. doi: 10.1177/1060028018761600. Epub 2018 Feb 26.

2018
ASL Città di Torino

Capetti AF; Cossu MV; Sterrantino G; Barbarini G; Di Giambenedetto S; De Socio GV; Orofino G; Di Biagio A; Celesia BM; Rusconi S; Argenteri B; Rizzardini G;

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. in BMC infectious diseases / BMC Infect Dis. 2017 Sep 30;17(1):658. doi: 10.1186/s12879-017-2755-4.

2017
ASL Città di Torino

Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G;

Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. in AIDS (London, England) / AIDS. 2017 Jan 28;31(3):455-457. doi: 10.1097/QAD.0000000000001351.

2017
ASL Città di Torino

Bonfanti P; Madeddu G; Gulminetti R; Squillace N; Orofino G; Vitiello P; Rusconi S; Celesia BM; Maggi P; Ricci E;

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology / J Clin Virol. 2017 Feb;87:30-36. doi: 10.1016/j.jcv.2016.11.015. Epub 2016 Dec 1.

2017
ASL Città di Torino

Marinaro L; Calcagno A; Ripamonti D; Cenderello G; Pirriatore V; Trentini L; Salassa B; Bramato C; Orofino G; D'Avolio A; Rizzi M; Di Perri G; Rusconi S; Bonora S;

Weight Gain: A Possible Side Effect of All Antiretrovirals. in Open forum infectious diseases / Open Forum Infect Dis. 2017 Nov 3;4(4):ofx239. doi: 10.1093/ofid/ofx239. eCollection 2017 Fall.

2017
ASL Città di Torino

Taramasso L; Ricci E; Menzaghi B; Orofino G; Passerini S; Madeddu G; Martinelli CV; De Socio GV; Squillace N; Rusconi S; Bonfanti P; Di Biagio A;

Treatment simplification to atazanavir/ritonavir?+?lamivudine versus maintenance of atazanavir/ritonavir?+?two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

2017
ASL Città di Torino

Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. in PloS one / PLoS One. 2017 Dec 5;12(12):e0189045. doi: 10.1371/journal.pone.0189045. eCollection 2017.

2017
ASL Città di Torino

Nozza S; Cozzi-Lepri A; Bai F; Rusconi S; Gori A; Cinque P; Ammassari A; Caramello P; Tambussi G; D'Arminio Monforte A; Marchetti G;

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. in PloS one / PLoS One. 2017 Jun 20;12(6):e0179254. doi: 10.1371/journal.pone.0179254. eCollection 2017.

2017
ASL Città di Torino

Squillace N; Ricci E; Quirino T; Gori A; Bandera A; Carenzi L; De Socio GV; Orofino G; Martinelli C; Madeddu G; Rusconi S; Maggi P; Celesia BM; Cordier L; Vichi F; Calza L; Falasca K; Di Biagio A; Pellicanò GF; Bonfanti P;

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. in PloS one / PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

2017
ASL Città di Torino

Rossetti B; Gagliardini R; Meini G; Sterrantino G; Colangeli V; Re MC; Latini A; Colafigli M; Vignale F; Rusconi S; Micheli V; Di Biagio A; Orofino G; Ghisetti V; Fantauzzi A; Vullo V; Grima P; Francisci D; Mastroianni C; Antinori A; Trezzi M; Lisi L; Navarra P; Canovari B; D'Arminio Monforte A; Lamonica S; D'Avino A; Zazzi M; Di Giambenedetto S; et alii...